CagriSema: studied together?

CagriSema

Also sold as cagrilintide plus semaglutide. Unlike the others here, this combination is being developed as a single pharmaceutical product by Novo Nordisk and has been through Phase 3 trials under the name CagriSema. It is the useful counter-example: this is what it looks like when a combination is studied as a combination.

This page answers one question: has anyone registered a trial of this combination? It is a different question from whether the ingredients have been studied separately, and the two answers are usually different. We do not publish doses, ratios or timing for any combination.

30On record

This combination has been studied as a combination

30 registered trials administer Cagrilintide and Semaglutide together: NCT06409130, NCT05813925, NCT07184086, NCT06534411, NCT07253285, NCT05996848, NCT07011667, NCT06797869, NCT06131372, NCT06131437, NCT05567796, NCT06716307, NCT06289504, NCT06780449, NCT05394519, NCT07597018, NCT04940078, NCT07010432, NCT04982575, NCT06267092, NCT06388187, NCT06207877, NCT06221969, NCT07282613, NCT06403761, NCT06323174, NCT07527195, NCT06065540, NCT06323161, NCT05669755. A registered trial is not a result — it records that the question was asked.

The ingredients, separately

Cagrilintide

AM833 · NNC0174-1213

An amylin analogue in Phase 3 for obesity, mostly studied in combination with semaglutide. Not approved anywhere.

What a well-evidenced compound looks like: dozens of trials, Phase 3 and 4, approved indications that match what it's sold for. Included as the yardstick.

Studied on its own

545

Registered trials

—Read this

Why combinations are studied separately

Two compounds given together can interact — in how they are absorbed, how long they last, or what they do at the same receptor. That is why regulators treat a fixed combination as its own product requiring its own trials. CagriSema is the example on this site of a combination developed and tested as one thing.

See all 42 compounds →